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The death rate for neurologic melioidosis is high. Whether 
certain Burkholderia pseudomallei strains are more likely 
than other strains to cause central nervous system infection 
and whether route of infection influences the neurotropic 
threat remain unclear. Therefore, we compared the virulence 
and dissemination of Australian clinical isolates collected 
during October 1989–October 2012 from patients with 
neurologic and nonneurologic melioidosis after intranasal 
and subcutaneous infection of mice in an experimental 
model. We did not observe neurotropism as a unique 
characteristic of isolates from patients with neurologic 
melioidsis. Rather, a distinct subset of B. pseudomallei 
strains appear to have heightened pathogenic potential for 
rapid dissemination to multiple tissues, including the central 
nervous system, irrespective of the infection route. This 
finding has valuable public health ramifications for initiating 
appropriate and timely therapy after exposure to systemically 
invasive B. pseudomallei strains. Increasing understanding 
of B. pseudomallei pathology and its influencing factors will 
further reduce illness and death from this disease.
Melioidosis is caused by the gram-negative bacterium Burkholderia pseudomallei. It incorporates a wide 
spectrum of clinical disease that ranges from severe, rap-
idly fatal, invasive disease to asymptomatic latent infec-
tion; thus, diagnosis is immensely challenging (1). No vac-
cine against melioidosis is currently available. The ability 
of B. pseudomallei to cause severe, rapidly fatal, invasive 
infections and to persist in the environment for extended 
periods, plus its intrinsic resistance to many antibacterial 
drugs, make B. pseudomallei a desirable candidate for use 
as a bioterrorism agent (1). Furthermore, B. pseudomallei 
can invade host cells, including macrophages, neutrophils, 
and other cells of the immune system, and persist within 
them (2,3). Without appropriate drug therapy, the death rate 
for melioidosis can exceed 90% (4,5).
Neurologic abnormalities occur in 3%–5% of 
melioidosis cases, and more than one quarter of those are 
fatal (5–8). Many similarities have been described regarding 
the clinical features of neurologic melioidosis in naturally 
infected animals and humans and in animal models infected 
with B. pseudomallei (6,9–15). Cranial nerve palsies 
and unilateral limb weakness are frequently described in 
patients with neurologic melioidosis (6,7,9,13,14). Flaccid 
paraparesis, commonly documented in animals with B. 
pseudomallei infection, also has been reported in humans 
(6,10,15). Often, microscopic and macroscopic abscesses 
are evident, and a predilection of B. pseudomallei for the 
brainstem and spinal cord has been suggested (9,12–14).
In contrast to patients with other forms of melioidosis, 
those with melioidosis with central nervous system (CNS) 
involvement are less likely to have predisposing risk 
factors, such as diabetes and chronic lung disease (6,8,9). 
Relatively little is known about the potential for different 
B. pseudomallei strains to cause severe disease, including 
whether particular strains are more likely to cause neurologic 
sequelae or whether CNS involvement is a consequence 
of the mode of delivery of B. pseudomallei. Neurologic 
melioidosis can result from direct invasion or through 
hematogenous spread (3,6,11,16,17). Initial suggestions 
that neurologic melioidosis might result from damage 
from immune or toxin-mediated mechanisms (6,12) has 
been supplanted by the recognition that direct invasion of 
brain and spinal cord by bacteria is evident on histologic 
examination of samples from case-patients who died (16). 
Furthermore, direct invasion of the brain by B. pseudomallei 
was recently demonstrated in an experimental model of 
melioidosis meningitis after delivery of intracellular bacteria 
by CNS-infiltrating CD11b+ immune cells (3).
Given the high rate of death from neurologic melioidosis, 
interest is increasing in improving understanding of its 
pathogenesis, particularly the potential for different B. 
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pseudomallei isolates to cause neurologic melioidosis and 
the influence of the route of transmission on entry into and 
dissemination within the CNS. Therefore, using a well-
characterized animal model of melioidosis (18) and clinical 
isolates of B. pseudomallei collected in the Northern 
Territory, Australia, during October 1989–October 2012 
(7), we sought to determine whether strains isolated 
from patients with neurologic melioidosis (neurologic 
isolates) showed higher virulence levels and neurotropism 
than isolates from patients with nonneurologic 
melioidosis (nonneurologic isolates) after respiratory and 
percutaneous exposure. 
Methods
B. pseudomallei Isolates
Eleven B. pseudomallei clinical isolates were analyzed. 
Six of these isolates were from patients with moderate to 
severe neurologic melioidosis, and 5 were from patients 
with nonneurologic melioidosis, both disseminated and 
localized cases (Table 1).
Animals
The C57BL/6–BALB/c mouse model is a well-
characterized model of differential susceptibility to B. 
pseudomallei (18). We included C57BL/6 and BALB/c 
mice to enable comparison of disease progression 
within immunocompetent and immune-impaired hosts, 
respectively. We purchased 8- to 12-week-old BALB/c and 
C57BL/6 mice from the Small Animal Breeding Facility, 
James Cook University (Townsville, QLD, Australia). 
Experiments were conducted in accordance with National 
Health and Medical Research Council guidelines and were 
approved by the institutional ethics committee (A1500).
Preparation and Delivery of B. pseudomallei Isolates
B. pseudomallei isolates were cultured in tryptic soy broth 
at 37°C to logarithmic phase. After washing in phosphate-
buffered saline (PBS), pH 7.2, bacteria were suspended 
to 108 CFU/mL. Serial 10-fold dilutions were prepared 
in sterile PBS to obtain required infectious doses. Doses 
were confirmed retrospectively by plating serial dilutions 
onto Ashdown agar (AA). To mimic natural routes of 
infection, intranasal or subcutaneous routes were used for 
inoculation with B. pseudomallei by previously described 
methods (18).
Determination of 50% Infectious Dose
Groups of 5 mice were inoculated intranasally and 
subcutaneously at 10-fold increasing doses of B. 
pseudomallei, ranging from 100 CFU to 107 CFU (18). 
Survival was monitored for 21 days, and moribund mice 
were euthanized. At necropsy, organs were observed for 
presence of visible abscesses. Spleens were homogenized 
and plated on AA to confirm the presence of B. 
pseudomallei in mice that died from their infection within 
the experiment period. Mice that survived to 21 days after 
infection were euthanized and underwent necropsy to 
determine whether abscesses were visible in spleen and 
liver. For mice infected subcutaneously, the subcutaneous 
adipose tissue at the site of infection was also assessed. 
Tissue homogenates were cultured on AA to confirm 
the presence or absence of persistent B. pseudomallei 
infection. We determined the 50% infectious dose (ID50) 
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Table 1. Clinical features of Burkholderia pseudomallei strains isolated from patients with neurologic and nonneurologic melioidosis 
and their virulence in C57BL/6 and BALB/c mice, Northern Territory, Australia, October 1989–October 2012* 
MSHR ID no. Age, y/sex Clinical feature Risk factor 
ID50 in mice (CFU)† 
Intranasal  Subcutaneous 
C57BL/6 BALB/c C57BL/6 BALB/c 
Neurologic         
 668‡ 53/M Severe neurologic signs None 4.1  104 2.9  102  7.1  103 <10 
 305§ 64/M Severe neurologic signs Alcohol use 2.6  102 2.6  102  3.7  104 <10 
 62‡ 24/M Severe neurologic signs None 2.2  102 6.3  101  2.4  102 <10 
 435‡ 37/M Severe neurologic signs Kava 5.0  102 1.3  102  <10 <10 
 1153§ 60/M Severe neurologic signs Diabetes mellitus 1.7 <10  <10 <10 
 3709‡ 14/M Moderate neurologic 
signs 
None 4.4  104 1.8  104  2.2  102 1.3  102 
Nonneurologic         
 1655‡ 61/F Chronic pulmonary Bronchiectasis >108 >108  >2  108 >2  108 
 465§ 67/M Septicemia Diabetes mellitus, chronic 
obstructive pulmonary 
disease 
1.3  105 1.1  103  8.3  105 <10 
 2138‡ 49/F Septicemia Diabetes mellitus 3.6  103 <10  4.2  103 1.2  101 
 346‡ 49/M Chronic pulmonary Alcohol use 8.5  104 6.0  104  6.0  105 7.0  105 
 543‡ 22/F Skin ulcer None 2.9  102 8.5  101  1.2  101 <10 
*ID50, 50% infectious dose; MSHR ID, neurologic isolate identification. 
†ID50 determined after intranasal and subcutaneous infection of C57BL/6 and BALB/c mice 
‡Nonfatal. 
§Fatal. 
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from the total number of mice that either died of their 
infection or had evidence of persistent infection 21 
days postinfection (dpi) using a modified version of the 
Reed and Meunch method (19). ID50 for neurologic and 
nonneurologic isolates are expressed as mean log10 CFU 
± the standard error of the mean (SEM). Virulence, as 
defined by the ID50 of B. pseudomallei isolates derived 
from patients with neurologic and nonneurologic 
melioidosis, were compared in BALB/c and C57BL/6 
mice after both intranasal and subcutaneous infection.
Determination of Bacterial Load
At specified time points, 5 mice were euthanized by 
cardiac puncture, and blood was collected into sterile 
tubes containing lithium heparin. Bacterial load in blood 
was determined by plating serial dilutions of whole 
blood in PBS onto AA and counting colonies after 24–
48 h incubation at 37°C. Immediately after collection of 
blood, the liver, spleen, lung, lymph nodes (cervical and 
inguinal), brain, and nasal-associated lymphoid tissue were 
aseptically excised. Tissue bacterial load was determined 
by homogenizing tissue in 1 mL of PBS and plating serial 
dilutions onto AA for colony counts. The detection limit of 
bacteria in tissues was 2 CFU. Data were expressed as the 
mean log10 CFU ± SEM.
Statistical Analysis
For statistical analysis, we used Graphpad Prism version 6 
(http://www.graphpad.com). Kaplan–Meier survival curves 
were used to compare susceptibility to infection with B. 
pseudomallei isolates after infection by different routes. ID50 
for neurologic and nonneurologic B. pseudomallei isolates 
were compared by using Student t test. Bacterial loads in 
organs after B. pseudomallei infection by different routes 
were tested for significance using 1-way analysis of variance 
based on normally distributed sets of data. Comparisons 
were considered to be significant at p<0.05.
Results
Although neurologic isolates tended to be more virulent 
(lower ID50) than nonneurologic isolates after intranasal 
infection, this finding did not reach statistical significance 
(Table 1). Consistent with previous evidence for differential 
susceptibility, C57BL/6 mice demonstrated greater 
resistance than BALB/c mice to B. pseudomallei infection, 
as indicated by their 10-fold higher ID50 (18).
Signs of CNS involvement (i.e., head tilt and/or circling, 
difficulty walking, limb paresis) developed after intranasal 
infection of BALB/c and C57BL/6 mice, typically 8–12 
dpi. This feature was not unique to neurologic isolates; 
head tilt and limb paralysis also were observed in mice 
infected with nonneurologic isolates. The development 
of neurologic signs corresponded with bacterial loads 
in brain, reaching >103 CFU. However, the data suggest 
that development of neurologic signs did not depend on 
the initial infectious dose because serial increases in the 
inoculating dose failed to cause a stepwise increase in 
number of C57BL/6 mice with neurologic signs (Table 2). 
Similar trends were observed after intranasal infection of 
BALB/c mice (data not shown).
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Table 2. Development of signs of neurologic involvement* in 
C57BL/6 mice after intranasal infection with Burkholderia 
pseudomallei strains isolated from patients with neurologic and 
nonneurologic melioidosis, Northern Territory, Australia, October 
1989–October 2012 
MSHR ID no.† 
Inoculating dose, 
CFU 
No. mice with neurologic 
signs/total mice infected 
Neurologic   
 668 2.9  103 1/5 
 2.9  104 0/5 
 2.9  105 2/5 
 2.9  106 2/5 
 305 2.6  103 0/5 
 2.6  104 1/5 
 2.6  105 3/5 
 2.6  106 0/5 
 62 2.2  103 1/5 
 2.2  104 1/5 
 2.2  105 2/5 
 2.2  106 1/5 
 435 3.0  103 0/5 
 3.0  104 3/5 
 3.0  105 2/5 
 3.0  106 2/5 
 1153 5.3  101 1/5 
 5.3  102 3/5 
 5.3  103 0/5 
 5.3  104 1/5 
 3709 2.2  103 0/5 
 2.2  104 0/5 
 2.2  105 0/5 
 2.2  106 0/5 
Nonneurologic   
 1655 1.1  104 0/5 
 1.1  105 0/5 
 1.1  106 0/5 
 1.1  107 0/5 
 465 6.6  103 0/5 
 6.6  104 0/5 
 6.6  105 2/6 
 6.6  106 1/6 
 2138 2.4  102 0/5 
 2.4  103 0/5 
 2.4  104 1/5 
 2.4  105 2/4 
 346 4.2  103 0/5 
 4.2  104 0/5 
 4.2  105 2/5 
 4.2  106 0/5 
 543 9.4  102 1/5 
 9.4  103 1/5 
 9.4  104 3/5 
 9.4  105 2/5 
*Head tilt, difficulty walking, limb paresis. 
†MSHR ID, neurologic isolate identification. 
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After subcutaneous infection with B. pseudomallei 
isolates, ID50 ranged from <10 CFU to >2 × 10
8 CFU in 
BALB/c and C57BL/6 mice. Consistent with intranasal 
infection, BALB/c mice were more susceptible than 
C57BL/6 mice to subcutaneous infection with B. 
pseudomallei, as indicated by their 10–100-fold lower ID50. 
Similar to findings after intranasal infection, neurologic 
isolates tended to be more virulent (lower ID50) than 
nonneurologic isolates after subcutaneous infection, 
although this finding did not reach statistical significance.
Mean ID50 was comparable for C57BL/6 mice after 
intranasal (3.2 × 104 CFU) or subcutaneous (9.3 × 104 
CFU) infection with neurologic isolates. Similarly, mean 
ID50 for BALB/c mice did not differ between intranasal (7.6 
× 102 CFU) and subcutaneous (8.1 × 102 CFU) infection. 
Neurologic isolates appeared to be more infectious for 
BALB/c mice when delivered subcutaneously rather than 
intranasally (p = 0.04). However, we did not observe this 
phenomenon for C57BL/6 mice.
We conducted a second series of studies to compare 
early bacterial load kinetics within tissues after intranasal 
and subcutaneous infection with B. pseudomallei. The 
purpose of these studies was to determine whether 
infection of the brain occurred more rapidly after 
intranasal than subcutaneous infection with isolates 
from neurologic melioidosis. The neurologic isolates, 
MSHR435 and MSHR1153, were associated with severe 
neurologic melioidosis whereby the CNS was suspected 
to be the primary site of infection and therefore represent 
isolates with high potential for direct CNS invasion after 
intranasal exposure in an animal model. BALB/c mice 
were inoculated with equivalent doses of B. pseudomallei 
intranasally or subcutaneously. Survival was monitored 
for 21 days. In addition, bacterial loads were determined 
in nasal-associated lymphoid tissue, draining lymph nodes 
(cervical or inguinal), blood, lung, brain, spleen, liver, and 
subcutaneous adipose tissue at the site of infection at 1, 
3, and 7 dpi. BALB/c mice tended to be more susceptible 
to MSHR435 when infected subcutaneously; the rate of 
death reached 100% within 18 days, although this finding 
was not statistically significant (p = 0.29) (Figure 1, panel 
A). However, the death rate for infection of BALB/c with 
MSHR1153 was significantly higher after subcutaneous 
inoculation; hind leg paresis developed within the second 
week after infection that necessitated euthanasia of 6 
of the 10 mice (p = 0.03, Figure 1, panel B). In contrast 
to subcutaneous infection, greater variability in disease 
progression was associated with intranasal inoculation of 
mice with B. pseudomallei, ranging from rapid systemic 
dissemination in some mice to low-level persistence in 
the respiratory tract with potential for clearance within a 
week after exposure. Infection was established in 100% 
of mice when MSRH435 or MSHR1153 was delivered 
subcutaneously. Consequently, the differences in overall 
death rates for mice after intranasal and subcutaneous 
infection reflect the variability in dissemination of B. 
pseudomallei after respiratory exposure.
Regardless of the route of infection, dissemination 
occurred rapidly; bacteria were detected not only at sites of 
infection but also in draining lymph nodes and spleen by 1 
dpi (Figure 2, panels A and B). Bacterial loads continued 
to increase significantly from 3 dpi (Figure 2, panels C, D) 
through 7 dpi (Figure 2, panels E, F), with comparable levels 
in spleen, liver, and lung after intranasal or subcutaneous 
infection for MSHR435 and MSHR1153. Bacterial loads in 
the brain of mice infected with MSHR435 and MSHR1153 
were low or undetectable within the first week after 
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Figure 1. Comparison of survival after intranasal and 
subcutaneous infection of BALB/c mice with equivalent doses of 
the neurologic Burkholderia pseudomallei isolates MSHR435 (5 
× 102 CFU) (A) and MSHR1153 (4.5 × 102 CFU) (B), Northern 
Territory, Australia, October 1989–October 2012. This inoculation 
dose was >50× the 50% infectious dose for MSHR435 and 
MSHR1153, delivered by intranasal or subcutaneous inoculation. 
Data are expressed as percentage survival; 10 mice were 
monitored within each group for 21 days postinfection.
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infection, consistent with the tendency for neurologic signs 
to develop after 8 dpi. The levels of bacteria recovered 
from brain after intranasal or subcutaneous infection with 
MSHR435 or MSHR1153 did not differ between 3 dpi 
and 7 dpi.
Discussion
Neurologic melioidosis is a serious, potentially fatal 
form of B. pseudomallei infection (5–7,16). The 
increased incidence of neurologic melioidosis in persons 
without recognized risk factors emphasizes the potential 
public health threat from this form of the disease. The 
contribution of bacteria- and host-specific factors in 
the pathogenesis of neurologic melioidosis is poorly 
understood, as are the potential roles of different modes 
of infection, such as percutaneous versus respiratory 
inoculation. Our study evaluated whether B. pseudomallei 
strains isolated from patients with neurologic melioidosis 
showed higher virulence in animal models of melioidosis 
than did strains isolated from patients with nonneurologic 
melioidosis. We found a trend for higher virulence for 
neurologic isolates than for nonneurologic isolates in an 
animal model, regardless of route of infection. However, 
neurotropism was not a unique characteristic of isolates 
from patients with neurologic melioidosis.
Consistent with the spectrum of clinical presentations 
of melioidosis, dissemination of B. pseudomallei in mice 
varied substantially. Neurologic signs developed in BALB/c 
and C57BL/6 mice 8–12 dpi. CNS involvement was not 
unique to neurologic isolates; we also observed head tilt 
and limb paralysis in mice infected with nonneurologic 
isolates. Although neurologic involvement was more 
commonly associated with intranasal inoculation, signs of 
CNS infection also occurred after subcutaneous infection. 
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Figure 2. Comparison of 
Burkholderia pseudomallei loads 
in organs of BALB/c mice at 
days 1 (A, B), 3 (C, D) and 7 (E, 
F) after intranasal (white bars) 
and subcutaneous (black bars) 
infection with the neurologic isolates 
MSHR435 (5 × 102 CFU; panels 
A, C, E) and MSHR1153 (4.5 × 102 
CFU; panels B, D, F) , Northern 
Territory, Australia, October 1989–
October 2012. Bacterial loads 
were assessed in NALT, cLN, iLN, 
blood, lung, brain, spleen, liver, 
and SAT at the indicated dpi. Five 
mice were assessed at each time 
point. Data are expressed as mean 
l;og10 CFU per tissue ± SEM. cLN, 
cervical lymph nodes; dpi, days 
postinfection; iLN, inguinal lymph 
nodes; NALT, nasal-associated 
lymphoid tissue; SAT, subcutaneous 
adipose tissue. Error bars indicate 
standard error of the mean.
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In most instances, subcutaneous infection resulted in 
localized abscesses in joints of hind limbs and vertebral 
column, causing hind leg paresis. However, neurologic 
signs occasionally developed in the absence of lesions at the 
subcutaneous injection site. When we compared intranasal 
and subcutaneous infection, we found a similar pattern of 
dissemination of neurologic isolates, which suggests that 
no predilection exists for neurologic isolates to invade by 
the respiratory route.
Our study provides evidence that B. pseudomallei 
isolates from patients with neurologic melioidosis do not 
demonstrate selective neurotropism in an experimental 
model. Rather, a subset of B. pseudomallei isolates 
appear to have unique virulence factors that facilitate 
rapid dissemination to multiple tissues, including the 
CNS, after both intranasal and subcutaneous exposure. 
We propose that this group of isolates is associated with 
severe disease progression and increased rates of death. 
This finding has valuable public health ramifications for 
initiating appropriate and timely therapy after exposure 
to systemically invasive B. pseudomallei strains. Studies 
focused on identifying virulence factors of B. pseudomallei 
that influence systemic spread, together with an improved 
understanding of the host–pathogen interactions that 
influence the progression to different forms of melioidosis, 
will be instrumental in identifying and evaluating future 
vaccine candidates and novel therapeutics for this 
potentially life-threatening disease.
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